KIRREL3-AS3: A Potential Drug Target and Biomarker (G283165)

Target Name: KIRREL3-AS3

NCBI ID: G283165

KIRREL3-AS3

Other Name(s): NCRNA00288 | KIRREL3 antisense RNA 3 | PRR10

KIRREL3-AS3: A Potential Drug Target and Biomarker

Introduction

KIRREL3-AS3 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the X chromosome expression profile, and its dysregulation has been implicated in various diseases, including cancer, neurodegenerative diseases, and mental disorders.

The X chromosome is a critical regulator of gene expression in females, and its dysfunction has been implicated in the development and progression of many diseases. Women carrying two X chromosomes (XX) are more susceptible to certain diseases, such as breast cancer, because of the higher concentration of X chromosomes in their bodies.

KIRREL3-AS3 is a non-coding RNA molecule that is located on the X chromosome and has been shown to play a role in regulating gene expression on this chromosome. It is a key regulator of the X chromosome expression spectrum, and its dysregulation has been implicated in the development and progression of various diseases.

Potential Drug Target

KIRREL3-AS3 has been identified as a potential drug target due to its involvement in the regulation of cellular processes that are important for human health and disease. One of its key functions is the regulation of cell cycle progression, which is the process by which cells divide and grow.

KIRREL3-AS3 has been shown to play a role in the regulation of the G1 phase of the cell cycle, which is the stage of growth and preparation for cell division. During this phase, KIRREL3-AS3 is involved in the accumulation of mutations in the DNA that can lead to the development of cancer.

In addition to its role in cell cycle regulation, KIRREL3-AS3 has also been shown to be involved in the regulation of apoptosis, which is the process by which cells die and are removed from the body. KIRREL3-AS3 has also been shown to play a role in the regulation of apoptosis in cancer cells, and its dysregulation has been implicated in the development and progression of various diseases.

Biomarker

KIRREL3-AS3 has also been identified as a potential biomarker for the diagnosis and prognosis of various diseases. Its dysregulation has been implicated in the development and progression of cancer, neurodegenerative diseases, and mental disorders.

In cancer, KIRREL3-AS3 has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis, which is the process by which new blood vessels are formed in the body. Its dysregulation has been implicated in the development and progression of various cancers, including breast, ovarian, and colorectal cancers.

In neurodegenerative diseases, KIRREL3-AS3 has been shown to be involved in the regulation of axon regeneration, which is the process by which the axons of nerve cells are replaced after injury or disease. Its dysregulation has been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its role in neurodegenerative diseases, KIRREL3-AS3 has also been shown to be involved in the regulation of mental disorders. Its dysregulation has been implicated in the development and progression of various mental disorders, including depression and anxiety.

Conclusion

In conclusion, KIRREL3-AS3 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its dysregulation has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and mental disorders. Further research is needed to fully understand the role of KIRREL3-AS3 in these diseases and to develop effective treatments.

Protein Name: KIRREL3 Antisense RNA 3

The "KIRREL3-AS3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIRREL3-AS3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets